Search results
Results From The WOW.Com Content Network
Chronic myelogenous leukemia treatment may include targeted therapy, immunotherapy, chemotherapy, stem cell transplant, donor lymphocyte infusion, and/or surgery. Learn more about the diagnosis and treatment of CML in this expert-reviewed summary.
Treatment options for people with chronic myeloid leukemia (CML) depend on the phase of their disease (chronic, accelerated, or blast phase), their age and overall health, other prognostic factors, and the availability of a stem cell donor with a matching tissue type (for a possible stem cell transplant).
Treatment options for people with chronic myeloid leukemia (CML) depend on the phase of their disease (chronic, accelerated, or blast phase), their age, other prognostic factors, and the availability of a stem cell donor with matching tissue type.
The goal of chronic myelogenous leukemia treatment is to eliminate the blood cells that contain the BCR-ABL gene. For most people, treatment begins with targeted therapy that may help achieve a long-term remission of the disease.
Targeted drugs work differently than standard chemotherapy drugs. They are often the most effective treatment for chronic myeloid leukemia (CML). Learn more here.
Chronic myeloid leukemia treatments include tyrosine kinase inhibitors, high-dose therapy with allogeneic transplant, and other medications. Get detailed information about chronic myeloid leukemia (CML) treatment options in this summary for clinicians.
Treatment for Chronic Phase CML. Tyrosine kinase inhibitor (TKI) therapy is standard treatment for chronic phase CML. TKIs are often successful at managing CML for long periods of time. The following TKIs are approved as primary treatment for chronic phase CML: Imatinib (Gleevec®) Dasatinib (Sprycel®) Nilotinib (Tasigna®) Bosutinib (Bosulif®)
Our doctors pioneered the standard approaches for treating CML, and depending on the stage of your disease may recommend imatinib, nilotinib, dasatinib, or other targeted therapies.
Chronic myeloid leukemia (CML) treatment plans. Treatment for CML can change depending on the phase of the disease: chronic, accelerated or blastic. In the chronic phase, patients typically receive targeted therapy. Younger patients may also be candidates for a stem cell transplant.
Current Treatment. In May 2001, the Food and Drug Administration (FDA) approved the new drug Gleevec (also know as Glivec or STI-571) for use in patients with chronic myelogenous leukemia. This drug is considered to represent a new direction in the treatment of cancer by its ability to target only the myeloid cells and leave healthy cells unharmed.